Encapsulation of an Oral Rabies Antigen, 01-9165Printer Friendly Version
Inclusive Dates: 10/01/99 - Current
Background - This project is evaluating a method for producing targeted microparticles for oral delivery of newly developing peptide and protein drugs. These drugs, which are susceptible to acid degradation in the stomach along with associated absorption problems, require special formulation. The rabies antigen is being used as a model drug for proving the proposed approach's viability, as well as providing a safe and convenient method of delivering the antigen for control of rabies in the animal population. This project is a joint effort of the Chemistry and Chemical Engineering Division and the Centers for Disease Control and Prevention (CDC).
Approach - SwRI has developed and patented (Patent Nos. 5,382,435 and 5,505,967) a pharmaceutical composition consisting of a shaped enteric matrix containing pharmaceutical-loaded particles, with the particles being no larger than approximately 10 micrometers in any dimension. The particles are alkali insoluble, allowing delivery of the pharmaceutical material to the Peyer's glands. The Peyer's glands, often referred to as Peyer's patches, contain phagocytic cells that capture solid particles of 10 micrometers or less that come into the intestine. This process is extremely important since particles cannot otherwise pass through the small intestinal lining. The small intestine consists of three main sections -- the duodenum, the jejunum, and the ileum. Most Peyer's glands are located in the ileum, with few in the jejunum and, on rare occasion, the duodenum. This patented method provides a system that allows oral doses of pharmaceuticals to be targeted for the Peyer's glands. The method can be highly beneficial in delivering protein drugs, such as the rabies antigen vaccine, to various mammals. The encapsulated rabies vaccine can be formulated to be stable for longer periods of time, and thus increase the shelf and active life of the bait formulations as well.
Accomplishments - This project has been delayed because of the time necessary to complete the corporate research and development agreement with the CDC. Recently, the agreement has been completed, and the research team is waiting for the antigen delivery from the CDC.